DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Wednesday morning. The brokerage issued a hold rating on the stock.

Several other research firms also recently commented on DBVT. HC Wainwright lifted their price objective on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a research note on Tuesday, December 10th.

DBV Technologies Trading Up 3.4 %

Shares of NASDAQ DBVT opened at $3.36 on Wednesday. The stock has a market cap of $69.11 million, a price-to-earnings ratio of -0.75 and a beta of 0.64. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $9.73. The stock’s 50-day moving average is $3.32 and its 200 day moving average is $3.86.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.